Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-11-23

FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Rising Pharma Holdings, Inc.)

View source ↗

Summary

The FDA has approved a supplemental application for escitalopram oxalate from Rising Pharma Holdings, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Escitalopram Oxalate (escitalopram oxalate)

Snippet

SUPPL AP for ESCITALOPRAM OXALATE (ESCITALOPRAM OXALATE)